title: Risk of tuberculosis reactivation with tofacitinib (CP-690550).
abstract: Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.
authors.affiliation: Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD, USA.
authors.forename: Mamoudou
authors.initials: M
authors.lastname: Maiga
authors.forename: Shichun
authors.initials: S
authors.lastname: Lun
authors.forename: Haidan
authors.initials: H
authors.lastname: Guo
authors.forename: Kathryn
authors.initials: K
authors.lastname: Winglee
authors.forename: Nicole C
authors.initials: NC
authors.lastname: Ammerman
authors.forename: William R
authors.initials: WR
authors.lastname: Bishai
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D004195:Disease Models, Animal; D007155:Immunologic Factors / Q000009:adverse effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D009169:Mycobacterium tuberculosis / Q000276:immunology / Q000472:pathogenicity; D010880:Piperidines; D011743:Pyrimidines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D014376:Tuberculosis / Q000139:chemically induced*
chemical_list: D000893:Anti-Inflammatory Agents; D007155:Immunologic Factors; D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib